Lincare Pharmacy Services INC.

Lincare Pharmacy Services INC. was paid $6.30M by Medicaid between Jan 2018 and Dec 2024, across 17 billing codes. Its largest line is J7605, Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms — 29% of everything it billed.

33Billing provider infoLINCARE PHARMACY SERVICES INC.
CARLSBAD, CA 92011

33aNPI1003970260assigned 12/21/2006

33bProvider typeDurable Medical Equipment & Medical Supplies

28Total paid$6.30M

24GClaims646,724

24DCodes billed17

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Durable Medical Equipment & Medical Supplies providers in California

Rank by total paid#60 of 946

Median peer was paid$15K

This provider vs. median413×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	105,521	$858K
2019	119,996	$983K
2020	129,256	$1.23M
2021	101,503	$1.20M
2022	80,234	$862K
2023	69,940	$794K
2024incomplete	40,274	$375K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J7605	Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms	29%	35,605	28,364	$1.82M
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	28%	23,071	19,477	$1.79M
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	15%	21,167	8,036	$948K
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	13%	63,407	49,826	$819K
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	6.6%	241,043	198,569	$417K
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	3.6%	115,954	91,123	$227K
J7613	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg	3.2%	115,617	93,983	$202K
G0333	Pharmacy dispensing fee for inhalation drug(s); initial 30-day supply as a beneficiary	<1%	10,606	8,702	$42K
J7644	Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram	<1%	15,386	12,078	$25K
Q0514	Pharmacy dispensing fee for inhalation drug(s); per 90 days	<1%	2,749	2,511	$11K
J3490	Unclassified drugs	<1%	339	312	$2K
99199	Unlisted special service, procedure or report	<1%	130	130	$910.80

5 more codes

A4216	Sterile water, saline and/or dextrose, diluent/flush, 10 ml	<1%	18	$624.63
A7003	Administration set, with small volume nonfiltered pneumatic nebulizer, disposable	<1%	1,268	$574.26
A7005	Administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable	<1%	229	$415.21
G0513	Prolonged preventive service(s) (beyond the typical service time of the primary procedure), in the office or other outpatient setting requiring direct patient contact beyond the usual service; first 30 minutes (list separately in addition to code for preventive service)	<1%	59	$265.89
E0570	Nebulizer, with compressor	<1%	76	$80.29

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSARANTAPOULAS, ANDREW (VICE PRESIDENT OF BUSINESS PROCE)